PDF Publication Title:
Text from PDF Page: 004
Biomedicines 2018, 6, 18 Biomedicines 2018, 6, x Biomedicines 2018, 6, x Figure 2. Superficial pigmented BCC at the right side of the nose treated with MAL-PDT using IPL as 4 of 8 4 of 8 4 of 8 Figure 2. Superficial pigmented BCC at the right side of the nose treated with MAL-PDT using IPL light source. Clinical and dermoscopic images showing: (A,B) arborizing telangectasias, large Figure 2. Superficial pigmented BCC at the right side of the nose treated with MAL-PDT using IPL as as light source. Clinical and dermoscopic images showing: (A,B) arborizing telangectasias, large blue/gray ovoid nests, multiple blue/gray globules before treatment and (C,D) partial clinical and light source. Clinical and dermoscopic images showing: (A,B) arborizing telangectasias, large blue/gray ovoid nests, multiple blue/gray globules before treatment and (C,D) partial clinical and dermoscopic response, defined by a decrease of BCC-specific dermoscopic features with persistence blue/gray ovoid nests, multiple blue/gray globules before treatment and (C,D) partial clinical and dermofscfeowpiacrrbeosrpizoingset,eldaenfignecetdasbiaysanddecbrluea/gsreaoyfgBloCbCul-essp,eactisfiixcmdeornmthossfcollpoiwc-fuepat.ureswithpersistenceof dermoscopic response, defined by a decrease of BCC-specific dermoscopic features with persistence few arborizing telangectasias and blu/gray globules, at six months follow-up. of few arborizing telangectasias and blu/gray globules, at six months follow-up. Figure 3. Three-dimensional (3D) images of partial clinical response: (A) before and (B) at 6 months Figure 3. Three-dimensional (3D) images of partial clinical response: (A) before and (B) at 6 months Figure 3. Three-dimensional (3D) images of partial clinical response: (A) before and (B) at 6 months following MAL-PDT using IPL as light source. following MAL-PDT using IPL as light source. Table 1. Complete clinical and dermoscopic clearance rates six months after last MAL-PDT using IPL following MAL-PDT using IPL as light source. as light source. Table 1. Complete clinical and dermoscopic clearance rates six months after last MAL-PDT using IPL Tablea1s.liCghotmsopulercte.clinical and dermoscopic clearance rates six months after last MAL-PDT using IPL as light source. Mean pain scosrBeCoCn a visual 11-point scale4(0, no pain; 10, insufferable p4a/i5n)(.80%) NMSC, nonmelanoma skin cancers; AK, actinic keratosis; sBCC, superficial BCC; BD, Bowen disease; NMSC Mean Pain during Treatment Clearance Rates (%) AK 3 18/20 (90%) NMSC Mean Pain during Treatment Clearance Rates (%) sBCC 4 4/5 (80%) AK 3 18/20 (90%) NMSC Mean Pain during Treatment Clearance Rates (%) BD 4 4/4 (100%) sBCC 4 4/5 (80%) NMSC, nonmelanoma skin cancers; AK, actinic keratosis; sBCC, superficial BCC; BD, Bowen disease; AK 3 18/20 (90%) BD 4 4/4 (100%) BD 4 4/4 (100%) Mean pain score on a visual 11-point scale (0, no pain; 10, insufferable pain). NMSC, nonmelanoma skin cancers; AK, actinic keratosis; sBCC, superficial BCC; BD, Bowen disease; Mean pain score on a visual 11-point scale (0, no pain; 10, insufferable pain).PDF Image | Photodynamic Therapy Pulsed Light Treatment of Nonmelanoma
PDF Search Title:
Photodynamic Therapy Pulsed Light Treatment of NonmelanomaOriginal File Name Searched:
biomedicines-06-00018.pdfDIY PDF Search: Google It | Yahoo | Bing
Cruise Ship Reviews | Luxury Resort | Jet | Yacht | and Travel Tech More Info
Cruising Review Topics and Articles More Info
Software based on Filemaker for the travel industry More Info
The Burgenstock Resort: Reviews on CruisingReview website... More Info
Resort Reviews: World Class resorts... More Info
The Riffelalp Resort: Reviews on CruisingReview website... More Info
| CONTACT TEL: 608-238-6001 Email: greg@cruisingreview.com | RSS | AMP |